Rare disease populations as pivotal proving grounds

EP: 1.regulatory certainty during rise of CRISPR

EP: 2.standardizing batch-to-batch quality

EP: 3.A trend away from Viral Vectors?

Now Viewing

EP: 4.Rare disease populations as pivotal proving grounds

EP: 5.Combined platform and modalities marriages.

EP: 6.Optimizing analytics toward full automation

EP: 7.Addressing manufacturing at scale for ATMP’s

In this exclusive BioPharm International Peer Exchange video series, Chris Spivey, Director of Industry Relations and Strategic Partnerships, talks with industry experts about various aspects of Cell and Gene Therapies with a focus on reducing manufacturing bottlenecks by creating smaller automated footprint installations, better integrating analytics advances including harnessing artificial intelligence, and above all lowering barriers to access by lowering costs while improving timelines.